Acquiring Company
Galera Therapeutics
Acquired Company
Obsidian Therapeutics
MalvernCambridgeHealthcareHealth CareBiotechnologyHealth CareDescription
Galera Therapeutics and Obsidian Therapeutics have signed a definitive merger agreement to create a combined company operating as Obsidian Therapeutics, Inc. The transaction is an all-stock merger supported by a private placement financing of $350 million. This merger aims to advance the clinical development of innovative TIL cell therapies for cancer treatment.
Who to call at Galera Therapeutics, and when
When Galera Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Galera Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Galera Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Galera Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Galera Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Obsidian Therapeutics?
Obsidian Therapeutics was acquired by Galera Therapeutics, based in Malvern. The deal was reported on April 14, 2026. Galera Therapeutics is focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera Therapeutics is privately held and operates in Healthcare.
When did Galera Therapeutics acquire Obsidian Therapeutics?
Galera Therapeutics's acquisition of Obsidian Therapeutics was reported on April 14, 2026. Galera Therapeutics and Obsidian Therapeutics have signed a definitive merger agreement to create a combined company operating as Obsidian Therapeutics, Inc. The transaction is an all-stock merger supported by a private placement financing of $350 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Obsidian Therapeutics do?
Obsidian Therapeutics, Inc. is a clinical biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.